| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Qiuyang Zheng, Guilin Li, Shihua Wang, Ying Zhou, Ke Liu, Yue Gao, Yulin Zhou, Liangkai Zheng, Lin Zhu, Qingfang Deng, Meiling Wu, Anjie Di, Lishan Zhang, Yingjun Zhao, Hongfeng Zhang, Hao Sun, Chen Dong, Huaxi Xu, Xin Wan. Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25. Science advances. vol 7. issue 1. 2021-02-06. PMID:33523861. |
down syndrome (ds), caused by trisomy of chromosome 21, is the most significant risk factor for early-onset alzheimer's disease (ad); however, underlying mechanisms linking ds and ad remain unclear. |
2021-02-06 |
2023-08-13 |
Not clear |
| Stylianos E Antonarakis, Brian G Skotko, Michael S Rafii, Andre Strydom, Sarah E Pape, Diana W Bianchi, Stephanie L Sherman, Roger H Reeve. Down syndrome. Nature reviews. Disease primers. vol 6. issue 1. 2021-02-02. PMID:32029743. |
trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of clinical features commonly known as down syndrome (ds). |
2021-02-02 |
2023-08-13 |
mouse |
| Diletta Valentini, Chiara Di Camillo, Nadia Mirante, Valentina Marcellini, Rita Carsetti, Alberto Villan. Effects of Pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study. Italian journal of pediatrics. vol 46. issue 1. 2021-02-02. PMID:32164747. |
children with down syndrome (ds) show a high susceptibility to recurrent infections (ri), caused by immune defects and abnormalities of the airways. |
2021-02-02 |
2023-08-13 |
Not clear |
| G Ahlström, A Axmon, M Sandberg, E Flygare Wallé. Health care utilisation among older people with Down syndrome compared to specific medical guidelines for health surveillance: a Swedish national register study. BMC health services research. vol 20. issue 1. 2021-02-02. PMID:33059705. |
specific medical guidelines for health surveillance exist for people with down syndrome (ds) since 25 years but knowledge of adherence to the guidelines is lacking. |
2021-02-02 |
2023-08-13 |
Not clear |
| Marcos Altable, Juan Moisés de la Sern. Down's syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 42. issue 2. 2021-02-02. PMID:33231770. |
down syndrome (ds) is the most common genetic cause of learning difficulties and intellectual disabilities. |
2021-02-02 |
2023-08-13 |
Not clear |
| Kirsten A Riggan, Christina Nyquist, Marsha Michie, Megan A Allys. Evaluating the Risks and Benefits of Genetic and Pharmacologic Interventions for Down Syndrome: Views of Parents. American journal on intellectual and developmental disabilities. vol 125. issue 1. 2021-01-28. PMID:31877259. |
researchers are investigating new technologies to mitigate or prevent symptoms of down syndrome (ds), including chromosome silencing and pharmacotherapy. |
2021-01-28 |
2023-08-13 |
human |
| Tarik F Hayda. Neurogenesis, Myelination, and Circuitry: The Case for a Distributed Therapeutic Regimen in Down Syndrome. American journal on intellectual and developmental disabilities. vol 125. issue 2. 2021-01-28. PMID:32058811. |
one of the overriding hopes of the down syndrome (ds) research community is to arrive at a better understanding of how trisomy 21 affects brain development and function, and that doing so will improve quality of life and independence for people with ds. |
2021-01-28 |
2023-08-13 |
Not clear |
| George T Capon. Current Research Approaches to Down Syndrome: Translational Research Perspectives. American journal on intellectual and developmental disabilities. vol 125. issue 2. 2021-01-28. PMID:32058816. |
this has been a major theme in down syndrome (ds) research since the mid-1980s when mouse models that approximate the condition of trisomy 21 (ts21) first became available ( das & reeves 2011 ). |
2021-01-28 |
2023-08-13 |
mouse |
| Anwar Baban, Nicole Olivini, Nicoletta Cantarutti, Federica Calì, Carmen Vitello, Diletta Valentini, Rachele Adorisio, Giulio Calcagni, Viola Alesi, Corrado Di Mambro, Alberto Villani, Bruno Dallapiccola, Maria Cristina Digilio, Bruno Marino, Adriano Carotti, Fabrizio Drag. Differences in morbidity and mortality in Down syndrome are related to the type of congenital heart defect. American journal of medical genetics. Part A. vol 182. issue 6. 2021-01-28. PMID:32319738. |
morbidity and mortality in down syndrome (ds) are mainly related to congenital heart defects (chds). |
2021-01-28 |
2023-08-13 |
Not clear |
| Bruno Pinto, Giovanni Morelli, Mohit Rastogi, Annalisa Savardi, Amos Fumagalli, Andrea Petretto, Martina Bartolucci, Emilio Varea, Tiziano Catelani, Andrea Contestabile, Laura E Perlini, Laura Cancedd. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome. Neuron. vol 108. issue 5. 2021-01-27. PMID:33027640. |
down syndrome (ds), the most frequent cause of genetic intellectual disability, is caused by a supernumerary chromosome 21, containing also genes related to the immune system. |
2021-01-27 |
2023-08-13 |
mouse |
| Mark Mapstone, Thomas J Gross, Fabio Macciardi, Amrita K Cheema, Melissa Petersen, Elizabeth Head, Benjamin L Handen, William E Klunk, Bradley T Christian, Wayne Silverman, Ira T Lott, Nicole Schup. Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands). vol 12. issue 1. 2021-01-26. PMID:32258359. |
we sought to determine whether similar metabolic pathways are implicated in adults with down syndrome (ds) who have increased risk for alzheimer's disease (ad). |
2021-01-26 |
2023-08-13 |
Not clear |
| Debmalya Sanyal, Kingshuk Bhattacharje. High Thyroid-stimulating Hormone Level in Down's Syndrome: A Mere Resetting of Hypothalamopituitary Axis in Subclinical Hypothyroidism? Indian journal of endocrinology and metabolism. vol 24. issue 5. 2021-01-26. PMID:33489845. |
hyperthyrotropinemia (ht) or reduced thyroid function in down syndrome (ds) is not uncommon, causes range from glandular dysgenesis to altered hypothalamopituitary axis. |
2021-01-26 |
2023-08-13 |
Not clear |
| April D Adams, Faycal Guedj, Diana W Bianch. Placental development and function in trisomy 21 and mouse models of Down syndrome: Clues for studying mechanisms underlying atypical development. Placenta. vol 89. 2021-01-25. PMID:31683073. |
down syndrome (ds) is the most common genetic disorder leading to developmental disability. |
2021-01-25 |
2023-08-13 |
mouse |
| Anca Angela Simionescu, Ana Maria Alexandra Stanesc. Missed Down Syndrome Cases after First Trimester False-Negative Screening-Lessons to be Learned. Medicina (Kaunas, Lithuania). vol 56. issue 4. 2021-01-25. PMID:32340394. |
here, we performed a descriptive analysis of down syndrome (ds) cases that were misdiagnosed and/or false-negative diagnosed after first trimester traditional screening via risk evaluation using ultrasound, biochemical markers, and different software programs. |
2021-01-25 |
2023-08-13 |
Not clear |
| Kari Knox, Justin Stanley, James A Hendrix, Hampus Hillerstrom, Taylor Dunn, Jillian Achenbach, Brian A Chicoine, Florence Lai, Ira Lott, Sanja Stanojevic, Susan E Howlett, Kenneth Rockwoo. Development of a symptom menu to facilitate Goal Attainment Scaling in adults with Down syndrome-associated Alzheimer's disease: a qualitative study to identify meaningful symptoms. Journal of patient-reported outcomes. vol 5. issue 1. 2021-01-22. PMID:33427993. |
as life expectancy of people with down syndrome (ds) increases, so does the risk of alzheimer's disease (ad). |
2021-01-22 |
2023-08-13 |
Not clear |
| Takeshi Kimura, Masato Takeuchi, Koji Kawakam. Utilization and efficacy of palivizumab for children with Down syndrome. Pediatrics international : official journal of the Japan Pediatric Society. vol 62. issue 6. 2021-01-19. PMID:31961027. |
although japan expanded the use of palivizumab for down syndrome (ds) in 2013 regardless of additional high-risk factors, there is not enough evidence to support its use. |
2021-01-19 |
2023-08-13 |
Not clear |
| b' C Delaby, D Alcolea, M Carmona-Iragui, I Ill\\xc3\\xa1n-Gala, E Morenas-Rodr\\xc3\\xadguez, I Barroeta, M Altuna, T Estell\\xc3\\xa9s, M Santos-Santos, J Turon-Sans, L Mu\\xc3\\xb1oz, R Ribosa-Nogu\\xc3\\xa9, I Sala-Matavera, B S\\xc3\\xa1nchez-Saudinos, A Subirana, L Videla, B Benejam, S Sirisi, S Lehmann, O Belbin, J Clarimon, R Blesa, J Pagonabarraga, R Rojas-Garcia, J Fortea, A Lle\\xc3\\xb. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Scientific reports. vol 10. issue 1. 2021-01-19. PMID:32514050.' |
in the present study, we analyzed nfl levels in the csf of 535 participants of the spin (sant pau initiative on neurodegeneration) cohort including cognitively normal participants, patients with alzheimer disease (ad), down syndrome (ds), frontotemporal dementia (ftd), amyotrophic lateral sclerosis (als), dementia with lewy bodies (dlb), progressive supranuclear palsy (psp) and corticobasal syndrome (cbs). |
2021-01-19 |
2023-08-13 |
human |
| Antonella Tramutola, Chiara Lanzillotta, Fabio Di Domenico, Elizabeth Head, D Allan Butterfield, Marzia Perluigi, Eugenio Baron. Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiology of disease. vol 137. 2021-01-15. PMID:31987911. |
considering that down syndrome (ds) and ad neuropathology share many common features, we investigated metabolic aspects of neurodegeneration, i.e., brain insulin resistance, in ds and whether it would contribute to early onset ad in ds population. |
2021-01-15 |
2023-08-13 |
Not clear |
| Julie C Lauterborn, Conor D Cox, See Wing Chan, Peter W Vanderklish, Gary Lynch, Christine M Gal. Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease. Brain pathology (Zurich, Switzerland). vol 30. issue 2. 2021-01-13. PMID:31410926. |
reduced spine densities and age-dependent accumulation of amyloid β and tau pathology are shared features of down syndrome (ds) and alzheimer's disease (ad). |
2021-01-13 |
2023-08-13 |
Not clear |
| Eric D Hamlett, Aurélie Ledreux, Anah Gilmore, Elena M Vazey, Gary Aston-Jones, Heather A Boger, Daniel Paredes, Ann-Charlotte E Granhol. Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome. Neurobiology of disease. vol 134. 2021-01-13. PMID:31678403. |
individuals with down syndrome (ds) develop alzheimer's disease (ad) with high penetrance and often exhibit working memory deficits coupled with degeneration of lc-ne neurons early in the progression of ad pathology. |
2021-01-13 |
2023-08-13 |
mouse |